Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars
New Site In Songdo Includes Lab And Office Space
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
You may also be interested in...
Samsung Bioepis Moves Swiftly To Denosumab Phase III
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.
Samsung Bioepis First To File EU Lucentis Rival
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D
Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer.